Lilly Fights Cymbalta 'Brain Zaps' Suit, Saying It Warned Docs

Law360, New York (January 29, 2013, 4:24 PM EST) -- Eli Lilly & Co. on Monday pressed a California federal judge to toss a proposed class action from consumers who allege they experienced “brain zaps” and other side effects when trying to stop using antidepressant Cymbalta, saying it properly warned doctors of risks.

The drugmaker’s motion to dismiss cites the so-called learned intermediary doctrine, which treats prescription medicines differently than other merchandise in recognizing that an expert — a physician — acts as a middleman between the manufacturer and the buyer.

“Because plaintiffs received Cymbalta only through...
To view the full article, register now.




Case Information

Case Title

Jennifer L Saavedra v. Eli Lilly and Company

Case Number



California Central

Nature of Suit

Contract: Other


Stephen V. Wilson

Date Filed

October 31, 2012

Law Firms


Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.